Drug Trial Radar · NCT07455851
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 26, 2026
Primary completion
Sep 30, 2033
Study completion Sep 30, 2033
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone. The study is looking at: * What side effects may happen from taking REGN17372 with linvoseltamab * How well REGN17372 and linvoseltamab, or linvoseltamab alone, work in treating multiple myeloma * What is the best dose of REGN17372 when given with linvoseltamab * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects) * If and how REGN17372 and linvoseltamab affect the overall quality of life, daily activities, symptoms and treatment side effects based on participant own feedback (Phase 2)
Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
LinvoseltamabDrug
Administered per protocol
REGN17372+LinvoseltamabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamabTime frame: Up to 35 days
- Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamabTime frame: Up to 5 years
- Severity of TEAEs associated with REGN17372 in combination with linvoseltamabTime frame: Up to 5 years
- Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugsTime frame: Within 12 weeks of starting cycle 1
- VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1
- Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugsTime frame: Within 12 weeks of starting cycle 1
- PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
South Western Sydney Local Health District - Liverpool Hosptial
Liverpool, New South Wales, Australia · Recruiting
Prince of Wales Hospital
Randwick, New South Wales, Australia · Recruiting
Illawarra Cancer care centre, Wollongong Hospital
Wollongong, New South Wales, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Evangelismos General Hospital
Athens, Attica, Greece · Recruiting
1st Health Region of Athens, Alexandra General Hospital of Athens
Athens, Attica, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.